2CUREX.ST Stock Analysis
2C
Uncovered
2cureX AB is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
2cureX AB engages in the research and development of anti-cancer treatments. The company is headquartered in Landskrona, Skane. The company went IPO on 2017-11-24. The firm focuses on the research and development of diagnostic substances to select treatment for cancer patients. The firm's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The firm's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. The company operates through 2cureX A/S.